Opioid-Induced Constipation (OIC) Market Insights, Epidemiology and Forecast 2025-2034 with Insights on SYMPROIC, MOVANTIK and BGP345A - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Opioid-Induced Constipation - Market Insights, Epidemiology, and Market Forecast - 2034" has been added to ResearchAndMarkets.com's offering.

The comprehensive report offers a detailed analysis of the market. It presents historical and projected epidemiological data, covering diagnosed prevalent cases, age-specific cases, cancer-related cases, and treated cases across seven major markets: the United States, EU4, the UK, and Japan, from 2020 to 2034. The report evaluates the existing treatment practices and unmet medical requirements, identifying potential business prospects.

Key Highlights:

• Opioid-induced constipation (OIC) arises from opioid-mediated inhibition of gastrointestinal motility and secretion via peripheral µ-opioid receptors.
• Affects 40-60% of patients on chronic opioid therapy, with a higher prevalence in women, older adults, and cancer pain populations.
• Treatment focuses on alleviating symptoms without compromising pain control; conventional approaches often provide limited relief.
• FDA-approved treatments include peripherally acting µ-opioid receptor antagonists (PAMORAs) such as RELISTOR, MOVANTIK, and SYMPROIC, as well as AMITIZA for non-cancer pain.
• BGP345A is an investigational candidate highlighting the unmet need in patients unresponsive to current PAMORAs.
• Persistent gaps in long-term efficacy and refractory patient care sustain opportunities for innovation, despite a mature market.

Epidemiology

The report offers data on patient populations and trends, illustrating the prevalence of OIC. This epidemiological data is valuable for understanding the disease burden across regions. OIC affects over 40% to 60% of patients without cancer receiving opioids.

Market Outlook

The market is expected to grow due to rising prevalence, technological advancements, and upcoming therapies. Research continues to hold hope for effective treatments and possibly a cure. Significant changes in the market are predicted during the forecast period.

Marketed Drugs:

• SYMPROIC (naldemedine): Approved for opioid-induced constipation in adults with chronic non-cancer pain.
• MOVANTIK (naloxegol): The first once-daily oral PAMORA for treatment in adults with chronic non-cancer pain.

Emerging Drugs:

• BGP345A represents efforts to advance novel treatment options for this condition. It is in Phase II of development.

Key Questions:

• What are the treatment goals for opioid-induced constipation?
• What are the challenges in managing opioid-induced constipation?
• What factors drive the growth of the opioid-induced constipation market?

Reasons to Buy:

• Understand the latest trends and dynamics driving the market.
• Gain insights into patient burden and disease prevalence.
• Identify growth opportunities and market potential.

Key Topics Covered:

1. Key Insights
2. Report Introduction
3. Market Overview at a Glance
   • Market Share (%) Distribution by Therapies in 2024
   • Market Share (%) Distribution by Therapies in 2034
4. Epidemiology and Market Methodology
5. Executive Summary
6. Key Events
7. Disease Background and Overview
   • Introduction
   • Types
   • Causes
   • Pathophysiology
   • Symptoms
   • Risk Factor
   • Diagnosis
     • Diagnostic Algorithm
     • Diagnostic Guidelines
   • Treatment and Management
     • Treatment Algorithm
     • Treatment Guidelines
8. Epidemiology and Patient Population
   • Key Findings
   • Assumptions and Rationale: The 7MM
   • Total Diagnosed Prevalent Cases of Opioid-induced Constipation in the 7MM
   • The US
   • EU4 and the UK
   • Japan
9. Patient Journey
10. Marketed Therapies
    • Key Cross Competition
    • SYMPROIC (naldemedine): Shionogi
    • MOVANTIK (naloxegol): RedHill Biopharma/ Astrazeneca
11. Emerging Therapies
    • Key Cross Competition
    • BGP345A: BioGaia Pharma
12. Opioid-Induced Constipation: Seven Major Market Analysis
    • Key Findings
    • Key Market Forecast Assumptions
    • Market Outlook
    • Attribute Analysis
    • Total Market Size of Opioid-Induced Constipation in the 7MM
    • Market Size of Opioid-Induced Constipation by Therapies in the 7MM
13. Key Opinion Leaders’ Views
14. Unmet Needs
15. SWOT Analysis
16. Opioid-Induced Constipation Market Access and Reimbursement
    • United States
    • EU4 and the UK
    • Japan
17. Appendix

A selection of companies mentioned in this report includes, but is not limited to:

• Shionogi
• RedHill Biopharma
• AstraZeneca
• Bausch Health

For more information about this report visit https://www.researchandmarkets.com/r/r60ubi

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.